大腸腺腫症遺伝子Apc, adenomatosis polyposis coli遺伝子のfloxedマウス。creマウスとの交配により組織特異的にノックアウトマウスを作成可能。エクソン14がloxPで挟まれている。 true ApcFlox14 ApcFlox14 Phage P1 loxP sites, mouse Apc genomic DNA C (3-6 months) FVB.Cg-Apc<tm2.1Cip>. Apc, adenomatosis polyposis coli is a member of the Wnt signaling pathway that is involved in development and tumorigenesis. This conditional knockout mice have a loxP-flanked Apc allele. Conditional Apc deficient mice can be generated by crossing with tissue-specific Cre mice. 条件を付加する。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Proc. Natl. Acad. Sci., 101, 17216-17221 (2004). Lab Invest., 84, 1619-1930 (2004).<br>研究成果の公表にあたって謝辞の表明を必要とする。<br>RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.<br>RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.<br>In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters. Cre/loxP system FVB;129P2(Cg)-Apc<tm2.1Cip>/GvnRbrc C（3〜6か月） <a href='https://brc.riken.jp/mus/pcr01872'>Genotyping protocol -PCR-</a> Developed by Dr. Marco Giovannini, INSERM France. RBRC01872 Marco Giovannini Marco Giovannini INSERM INSERM Sibling Mating In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Proc. Natl. Acad. Sci., 101, 17216-17221 (2004). Lab Invest., 84, 1619-1930 (2004).In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.<br>RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.<br>In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters. Sibling Mating (Homozygote x Homozygote) Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol> ApcFlox14 Developed by Dr. Marco Giovannini, INSRM France. FVB/N background.